{"nctId":"NCT02305797","briefTitle":"EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)","startDateStruct":{"date":"2015-01"},"conditions":["Generalized Anxiety Disorder (GAD)"],"count":495,"armGroups":[{"label":"EDG004","type":"EXPERIMENTAL","interventionNames":["Drug: Extended-release lorazepam"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Extended-release lorazepam","otherNames":["EDG004"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women between the ages of 18-65 years and\n* Diagnosed with GAD and\n* No other psychiatric conditions, and are otherwise medically healthy.\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42)","description":"HAM-A Total Score was rated by the clinician. Scores range from 0 to 56. A lower score is favorable. Baseline was defined as the last non-missing value prior to receiving double-blind study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.01","spread":"0.47"},{"groupId":"OG001","value":"-8.93","spread":"0.48"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Visit 7 (Day 42)","description":"Measured on a 7-point scale 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill. Baseline was defined as the last non-missing value prior to receiving double-blind study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":"0.072"},{"groupId":"OG001","value":"-1.10","spread":"0.071"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":247},"commonTop":["Somnolence","Fatigue","Headache","Dizziness","Nausea"]}}}